Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168324
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers

NCT02033668
View directory record Official record
Conditions
Atrophy, Geographic
Interventions
GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 2 Interventional

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

NCT00713518
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Not applicable Interventional

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

NCT05857943
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
AEYE-DS Software
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Fayetteville, Arkansas • Orlando, Florida • Jackson, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 20, 2026, 3:08 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525
View directory record Official record
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 4 Interventional Results available

Study for Recalcitrant Age Related Macular Degeneration

NCT01543568
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
aflibercept 2.0 mg
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 20, 2026, 3:08 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525613
View directory record Official record
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 20, 2026, 3:08 PM EDT
Completed No phase listed Observational

Eye to Brain Connection

NCT05215782
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 20, 2026, 3:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tracking Optical Coherence Tomography

NCT00343603
View directory record Official record
Conditions
Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 20, 2026, 3:08 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)

NCT07855770
View directory record Official record
Conditions
Retinal Detachment Rhegmatogenous
Interventions
Intravitreal 100% C3F8 Injection, Pars plana vitrectomy or pars plana vitrectomy with scleral buckle
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

NCT00533520
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
ranibizumab
Drug
Lead sponsor
Brandon G. Busbee, MD
Other
Eligibility
50 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 20, 2026, 3:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Time Outside Target Oxygen Saturation Range in Preterm Infants and Long Term Outcomes and Preterm Infants

NCT00845624
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
1 Day to 12 Months
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 20, 2026, 3:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327
View directory record Official record
Conditions
Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Interventions
Ocufolin
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 3:08 PM EDT
Not listed Not applicable Interventional

Eye Shields for Infants After Dilated Exam

NCT04519060
View directory record Official record
Conditions
Infant, Newborn, Disease, Pain, Retinopathy of Prematurity, Eye Diseases
Interventions
phototherapy eye shield
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 1 Year
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 20, 2026, 3:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 20, 2026, 3:08 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Vascular Reparative Mechanism in Diabetes

NCT02119689
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Diabetic Patients, Healthy Controls
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 3:08 PM EDT
Active, not recruiting No phase listed Observational

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

NCT05605782
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Exchanges With Avocado and Mango in Pre-diabetes

NCT05353790
View directory record Official record
Conditions
Pre Diabetes, Vascular Stiffness, Vascular Dilation, Cognitive Change, Retinal Vascular
Interventions
Meals + snacks: control, Meals + snacks: Avocado mango
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
25 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 20, 2026, 3:08 PM EDT
Terminated Phase 3 Interventional Results available

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247479
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab, Sham
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 20, 2026, 3:08 PM EDT
Completed No phase listed Observational

Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity

NCT00279669
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 20, 2026, 3:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

NCT00996437
View directory record Official record
Conditions
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab, Saline
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 20, 2026, 3:08 PM EDT
Terminated Not applicable Interventional

The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

NCT01880372
View directory record Official record
Conditions
Moderate Non-proliferative Diabetic Retinopathy
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
Ferris State University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Big Rapids, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 3:08 PM EDT